Ripertamab Injection

This product is suitable for newly diagnosed adult patients with CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with an international prognostic index (IPI) of 0 to 2 points. It should be treated in combination with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone).
Repatuzumab is a human-mouse chimeric monoclonal antibody that can specifically bind to the transmembrane antigen CD20. The CD20 antigen is located on the surface of pre-B and mature B lymphocytes. After binding to the CD20 antigen on B cells, this product initiates an immune response to mediate B cell lysis. The mechanisms of B cell lysis may include: complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).